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Abstract (3)-Galanthamine (GAL), an alkaloid from the
flower, the common snowdrop (Galanthus nivalis), shows anti-
cholinesterase activity. This property has made GAL the target
of research as to its effectiveness in the treatment of Alzheimer’s
disease. We have solved the X-ray crystal structure of GAL
bound in the active site of Torpedo californica acetylcholinester-
ase (TcAChE) to 2.3 Aî resolution. The inhibitor binds at the base
of the active site gorge of TcAChE, interacting with both the
choline-binding site (Trp-84) and the acyl-binding pocket (Phe-
288, Phe-290). The tertiary amine group of GAL does not
interact closely with Trp-84; rather, the double bond of its
cyclohexene ring stacks against the indole ring. The tertiary
amine appears to make a non-conventional hydrogen bond, via its
N-methyl group, to Asp-72, near the top of the gorge. The
hydroxyl group of the inhibitor makes a strong hydrogen bond
(2.7 Aî ) with Glu-199. The relatively tight binding of GAL to
TcAChE appears to arise from a number of moderate to weak
interactions with the protein, coupled to a low entropy cost for
binding due to the rigid nature of the inhibitor.
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1. Introduction
According to the ‘cholinergic hypothesis’, Alzheimer’s dis-
ease (AD) is associated with cholinergic insu⁄ciency [1^3].
This serves as the rationale for use of cholinergic agonists
[4,5] and cholinesterase inhibitors [6,7] for the symptomatic
treatment of AD in its early stages. Indeed, cholinesterase
inhibitors are the only drugs so far approved for treatment
of AD. These drugs include natural substances, such as the
alkaloids, physostigmine [8] and huperzine A [9], and syn-
thetic compounds, such as tacrine, under its trade name,
Cognex0 [10], SDZ ENA-713, also known as Exelon0 [11],
metrifonate [12] and E2020, under its trade name, Aricept0
[13,14].
Galanthamine (4a,5,9,10,11,12-hexahydro-3-methoxy-11-
methyl-6H-benzofuro[3a,3,2-ef][2]-benzazepin-6-ol ; GAL; see
Fig. 1) is an alkaloid found in the bulbs and £owers of the
common snowdrop (Galanthus nivalis) and of several other
members of the Amaryllidaceae family. The active ingredient
was discovered accidentally by a Bulgarian pharmacologist in
wild Caucasian snowdrops in the early 1950s [15]. The plant
extracts were used initially to treat nerve pain and poliomye-
litis. As a natural compound, GAL has since been tested for
use in anesthesiology [16] and for treatment of many human
ailments, from facial nerve paralysis to schizophrenia and
various dementia [17^19]. It is marketed as a hydrobromide
salt under the name Reminyl1.
GAL displays 53-fold selectivity for human erythrocyte ace-
tylcholinesterase (AChE) over butyrylcholinesterase (BChE),
with IC50 values of 0.35 WM for erythrocyte AChE and 18.6
mM for plasma BChE [20]. An IC50 of 652 nM has been
recorded for Torpedo californica AChE (TcAChE) (T. Lewis
and C. Personeni, unpublished results). Interestingly, it dis-
plays 10-fold lower potency towards human brain AChE
than towards the erythrocyte enzyme [21]. In addition to serv-
ing as a cholinesterase inhibitor, GAL is also a nicotinic acti-
vator, acting both on ganglionic and muscle receptors [22,23]
and on nicotinic receptors in the brain [24]. Nicotinic modu-
lation represents a new and promising approach in Alzheimer
research [25^30]. A recent report suggests that stimulation of
nicotinic receptors may be associated with diminished appear-
ance of amyloid plaques, one of the hallmarks of AD [31].
The double action of GAL, as both an anticholinesterase and
a nicotinic activator, has rendered it a promising candidate
drug for the treatment of AD. Indeed, phase III clinical trials
in Europe for the treatment of AD were recently completed
[32], although approval has not yet been granted.
Structure-based drug design is an important tool in the
development of second-generation candidate drugs based on
a lead compound [28,33^35]. Although computerized docking
programs are becoming increasingly sophisticated, the X-ray
analysis of a ligand-protein structure often yields crucial in-
formation. Indeed, in the case of AChE, determination of the
three-dimensional (3D) structures of the appropriate ligand-
AChE complexes was a prerequisite for making correct struc-
tural assignments for huperzine A [36] and E2020 [14], as well
as for the snake venom toxin, fasciculin [37]. In the case of
GAL, too, docking protocols suggest more than one possible
orientation (Fletcher, R., Viner, R., Lewis, T., unpublished
results). Determination of the 3D structure of a GAL-AChE
complex would obviously resolve the issue. Furthermore,
knowledge of the structure of the complex would also allow
us to rationalize results of recent synthetic modi¢cations [38]
aimed at improving binding characteristics of GAL to AChE.
In the following, we present the X-ray crystal structure, at 2.3
Aî resolution, of the GAL-TcAChE complex.
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2. Materials and methods
2.1. Crystallization and data collection
TcAChE was puri¢ed and crystallized as described [36]. GAL was
purchased from Sigma (G1160, lot # 56H0191, hydrobromide form).
Three crystals of TcAChE were harvested and transferred to a drop
containing mother liquor and 10 mM GAL. After 2 days, they were
transferred to a second solution of mother liquor containing 20 mM
GAL. All work was done at 4‡C. After 2 more days, a crystal was
transferred to oil, mounted in a cryo-loop, placed on the goniostat
and £ash-cooled to 100 K in an Oxford Systems Cryostream. The X-
ray source was a Rigaku FR-C rotating anode running at 50 KV/100
mA. Images were collected with a Rigaku RAXIS-IIC. Data collec-
tion statistics are summarized in Table 1. Data processing was carried
out with DENZO/SCALEPACK [39]. Data were truncated with the
CCP4 [40] program TRUNCATE, and a list of randomly generated
test re£ections was added from a master list for the trigonal crystal
form of TcAChE using CAD and FREERFLAG. Re£ections were
output with MTZ2VARIOUS to a format suitable for CNS.
2.2. Re¢nement
The protein was re¢ned in CNS [41], initially by use of rigid body
re¢nement. Subsequently, di¡erence maps (Fo3Fc) and 2Fo3Fc
maps were used to ¢t the GAL molecule, two carbohydrate moieties
and 93 water molecules (to 4.5c). The initial electron density for the
inhibitor was unambiguous, as seen in Fig. 2. The program XtalView
[42] was used for all model building. The model used for GAL was
taken from the crystal structure ([43]; CSD code SIBHAM) of the
neutral compound. Individual B-re¢nement was carried out, followed
by simulated annealing (torsion dynamics mode [44]), followed again
by individual B-factor re¢nement. Inspection of positive peaks in dif-
ference maps to 4c showed an additional 51 water molecules, as well
as a continuous stretch of density near the top of the active site gorge
which was modeled as a PEG trimer. Inspection of the entire protein
resulted in a few minor changes to side chain positions outside the
area of the active site. The model was further re¢ned by positional
maximum-likelihood minimization and by individual B-factor re¢ne-
ment. The results are summarized in Table 2.
3. Results
The overall mode of binding of GAL to TcAChE is shown
in Fig. 3. The inhibitor binds at the base of the active site
gorge, spanning the acyl-binding pocket and the choline-bind-
ing site, viz. the indole ring of Trp-84. There appear to be two
classic hydrogen bonds formed with protein atoms (Fig. 4).
One is between the hydroxyl group of the inhibitor and Glu-
199 OO1 (2.7 Aî ). The hydroxyl group also interacts with two
water molecules. One water molecule (3.1 Aî ) is that which is
bound in the oxyanion hole by the three NH groups of Gly-
118, Gly-119 and Ala201. It is also bifurcated with the oxygen
atom of the dihydrofuran ring of the inhibitor (3.1 Aî ). A
second water molecule is 3.3 Aî away and interacts also with
Tyr-130 OR and Gly-117 N. The second possible hydrogen
bond to a protein atom involves the hydroxyl group of Ser-
200, whose hydrogen may be bifurcated between His-440 NO2
Fig. 1. GAL.
Table 1
Collection and processing statistics
Oscillation angle 0.5‡
Total number of frames 72
Total number of re£ections 215 846
Resolution range 30^2.3 Aî
Number of unique re£ections 43 422
Redundancy 0 1 2 3 4 s 5
% Re£ection 1.3 20.8 47.1 24.8 5.0 1.0
Average redundancy (weighted) 3.1
Overall completeness 98.7%
Completeness in highest resolu-
tion shell
97.1%
Overall Rmerge 7.7%
Rmerge in highest resolution shell
(2.38^2.30 Aî )
39%
Fig. 2. Electron density map (Fo3Fc) from the GAL-TcAChE com-
plex after rigid body re¢nement. The map shows unambiguous den-
sity for GAL bound in the active site of the enzyme. Contouring
level is at 3c, shown in thin blue lines. Only contours within 2.0 Aî
of the inhibitor are shown. GAL is rendered as a ball-and-stick
model, with carbon atoms colored green. Selected protein residues
are rendered as sticks, with carbon atoms colored yellow and la-
beled appropriately. The double bond of the cyclohexene ring in
GAL is indicated by the arrow (picture made with X¢t [42] and
Raster3d [54]).
Table 2
Re¢nement results
Resolution range 30.0^2.3 Aî
Number of protein atoms 4 211
Number of non-protein atoms
Solvent (water, PEG) 144, 10
Carbohydrate atoms 28
Inhibitor 21
Rwork 21.3%
Rfree (5% of re£ections) 25.0%
rms bond deviations 0.017 Aî
rms angle deviations 1.8‡
FEBS 23067 9-12-99 Cyaan Magenta Geel Zwart
H.M. Greenblatt et al./FEBS Letters 463 (1999) 321^326322
and the oxygen of the O-methyl group of the inhibitor. There
may also be a non-classical hydrogen bond between the N-
methyl group of the inhibitor and Asp-72 ON2 (3.4 Aî ), since
the methyl group is expected to carry some of the positive
charge of the amine. The unexpected presence of a PEG mol-
ecule in the active site gorge gives rise to an interesting inter-
action between the terminal hydroxyl group of the PEG mol-
ecule and the tertiary amine of GAL (2.8 Aî ). The terminal
hydroxyl group, in turn, forms an aromatic hydrogen bond
[45,46] with Phe-330. A water molecule could presumably ful-
¢l the same role in the absence of PEG. The rest of the
interactions between the inhibitor and the protein appear to
be non-polar. This is particularly noteworthy, since the pro-
tonated tertiary amine group does not interact with Trp-84 or
Phe-330 analogously to the interaction which is believed to
occur between the quaternary amine of the natural substrate
(acetylcholine) and the enzyme, and has been observed for a
number of inhibitors [36,47,48]. In fact, the nitrogen and its
three substituents are quite removed from Trp-84, the closest
approach being between C11 of the inhibitor and CQ (3.6 Aî )
and CN1 (3.7 Aî ) of the indole ring. The next methylene group
in the tetrahydroazepine ring (C12) makes three contacts with
the indole ring, and the rest of the interactions with Trp-84
involve the cyclohexene ring of GAL. The double bond in the
cyclohexene ring stacks against the Z system of the indole ring
of Trp-84. Saturation of this double bond (to give lycoramine)
greatly reduces the binding a⁄nity of the inhibitor (T. Lewis,
C. Personeni, unpublished results). On the opposite side of the
gorge, the O-methoxy group of GAL occupies the acyl-bind-
ing pocket, contacting Phe-288 and Phe-290.
Fig. 3. Stereo view of binding of GAL in the active site gorge of TcAChE. The solvent accessible surface of the protein (without waters and
without ligands) was calculated by use of the program MSMS [55] with a probe radius of 1.4 Aî . Only those parts of the surface within 9.0 Aî
of the bound inhibitor are visible, and the surface is 30% transparent, allowing visualization of some of the underlying protein residues. The
surface has also been clipped to reveal the interior side, and has been color-coded such that blue indicates those parts of the surface whose
underlying atoms are between 4.0 and 3.0 Aî from any atom of the inhibitor, and pink indicates distances of less than 3.0 Aî from the protein
atoms to the inhibitor. Only a small portion of pink surface is visible in this orientation, located below the O-methyl group of the inhibitor, in
the acyl-binding pocket. GAL has been rendered as a ball-and-stick model whose carbon atoms are colored green. Selected protein residues are
shown as stick models with yellow carbon atoms. Water molecules are red spheres, and the PEG200 trimer/tetramer is rendered as a ball-and-
stick model whose carbon atoms are colored pink (picture made with DINO [56] and rendered in POV-rayz [57]).
Fig. 4. Stereo view of possible hydrogen bonds between GAL and TcAChE. The inhibitor is displayed as a ball-and-stick model, with green
carbon atoms. The protein residues are rendered as stick models with yellow carbon atoms (DINO/POV-ray).
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4. Discussion
Initial inspection of the GAL-TcAChE complex does not
reveal any speci¢c interactions which could account for the
tight binding observed. GAL is not a transition state ana-
logue, which, of all the structures on the reaction coordinate,
bind most tightly to the enzyme [49]. Nor are there any
charge-charge interactions between the inhibitor and the en-
zyme. In fact, the only charged group in the inhibitor interacts
rather indirectly with residues of the protein (through a sol-
vent molecule to Phe-330, possibly via a methyl hydrogen to
Asp-72, and via a methylene hydrogen with the Z system of
Trp-84). It must be assumed that the binding energy for GAL
comes from a number of smaller enthalpic contributions,
coupled to an unusually small entropic penalty. This latter
point arises from the rigidity of the molecule, which allows
the numerous interactions to occur with minimal loss of en-
tropy. A similar concept is utilized in the tight binding of
multisubstrate analogues ([50], see Fersht [51]).
Recent attempts to produce synthetic derivatives of GAL
with higher binding a⁄nities [38] showed that conversion of
the tertiary amine to an iminium ion (See Fig. 5a) increased
the a⁄nity for electric eel AChE (EeAChE) by 4.5-fold. In an
attempt to produce bifunctional ligands which would interact
with Trp-279 at the top of the gorge, a phthalimido group was
attached to the nitrogen (Fig. 5b), via alkyl spacers of varying
lengths. This had only a moderate e¡ect on the IC50, with a
maximal decrease of 5.6-fold (four-carbon spacer), and a max-
imal increase of only 1.3-fold (eight-carbon spacer), relative to
GAL. Interestingly, a molecule combining both the iminium
and pthalimido (eight-carbon spacer) modi¢cations (Fig. 5c)
showed a 36-fold increase in a⁄nity. The crystal structure of
GAL bound in the active site of TcAChE justi¢es the above
rationale for creating bis-interacting derivatives, since the ni-
trogen atom is oriented up the gorge. This is in contrast to the
results obtained when attachment of the alkyl-phthalimido
functionality was via the hydroxyl group of GAL. The com-
pounds so obtained inhibit AChE approximately two orders
of magnitude more weakly than GAL itself. Since the ob-
served binding mode of GAL places the hydroxyl group in
an area of restricted volume, additions to this part of the
molecule would presumably force GAL to bind in a di¡erent
fashion. What is not apparent is why the iminium derivative
should be a better inhibitor than native GAL, since the latter
is presumably protonated at pH 5.6. One possibility is that the
Fig. 5. (a) Comparison of GAL (left) with its iminium derivative
(right). This is the same structure as in Fig. 1, but drawn here to
show some of the stereochemistry. (b) GAL with N-linked phthali-
mide group using variable length alkyl chain. (c) Iminium derivative
of GAL with N-linked phthalimide group, as in (b).
Fig. 6. Stereo view comparing binding of GAL and huperzine A in the active site of TcAChE, showing the main chain conformational change
(Gly-117) associated with binding of huperzine A. GAL and associated protein residues are rendered as green stick models, while huperzine
and associated protein residues are rendered as thin pink stick models. Water molecules associated with the GAL structure are shown as red
spheres, while those from the huperzine structure are displayed as smaller pink spheres (DINO/POV-ray).
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planar geometry of the nitrogen atom allows closer interaction
of the N-methyl group with Asp-72, resulting in a stronger
hydrogen bond.
Another AD drug, huperzine A [36,52], shares common
binding characteristics with GAL (Fig. 6). Both molecules
have a bent hinge shape and, in both cases, the hinge is ori-
ented similarly when the ligand is bound to TcAChE. Both
molecules pack against the face of Trp-84 and make few direct
hydrogen bonds to the protein. Nevertheless, there are several
major di¡erences in their binding modes. Thus, GAL does not
induce a main chain conformational change at Gly-117 as
does huperzine A. Moreover, the orientation of the side chain
of Phe-330 di¡ers in the two complexes. Furthermore, the
primary amino group of huperzine A interacts much more
closely with the indole ring of Trp-84 than does the tertiary
amine of GAL. Finally, GAL does not exhibit the slow bind-
ing kinetics observed for huperzine A [53]. A partial answer to
the question of why GAL binds with a tightness comparable
to huperzine A, despite apparent lack of direct interaction
between the amine group and Trp-84, may lie in the fact
that GAL ¢lls more of the active site volume, since it also
binds in the acyl-binding pocket. Furthermore, one of the
direct hydrogen bonds with the protein involves a charged
residue (Glu-199), which is not the case for huperzine A.
5. Conclusions
The structure of the complex of GAL and TcAChE shows
that GAL binds at the base of the gorge interacting with both
the acyl-binding pocket and the principal quaternary ammo-
nium-binding site, the indole ring of Trp-84. The high a⁄nity
displayed by the inhibitor for AChE appears to come from a
number of moderate to weak interactions accompanied by a
low entropic cost owing to its rigid structure.
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